PETVIVO HOLDINGS, INC. TO PROVIDE COMPANY UPDATE RELATED TO THE MWI DISTRIBUTION AGREEMENT AND DISCUSS RESULTS FOR THE FISCAL YEAR ENDED MARCH 31, 2022
June 28 2022 - 11:00AM
PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging
biomedical device company focused on the commercialization of
innovative medical therapeutics for companion animals, will provide
an update regarding the MWI Distribution Services Agreement and
discuss financial results for the year ended March 31, 2022, on
Wednesday, June 29, 2022 at 4:00 p.m. CT (5:00 p.m. ET).
Attendees of the live webcast of the conference
call and related earnings release materials can register and access
the webcast on PetVivo’s Investor Relations website at:
https://audience.mysequire.com/webinar-view?webinar_id=4247f378-9329-46f0-adcf-44720e7f5ae6
A replay of the webcast will be available
through the same link following the conference call. Participants
can also access the call using the dial-in details below.
Date: Wednesday, June 29, 2022 Time: 4:00 p.m. CT (5:00 p.m.
ET)Dial-in number: +1 (346) 248-7799 Conference ID:
97245185036Passcode: 740720
Disclosure Information
PetVivo uses and intends to continue to use its
Investor Relations website as a means of disclosing material
nonpublic information and for complying with its disclosure
obligations under Regulation FD. Accordingly, investors should
monitor the company’s Investor Relations website, in addition to
following the company’s press releases, SEC filings, public
conference calls, presentations and webcasts.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV and PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of dogs and horses in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of twenty-one
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG™, a
veterinarian-administered, intraarticular injection for the
management of osteoarthritis in dogs and horses, was made available
for commercial sale in September, 2021.
CONTACT:
John Lai, CEOPetVivo Holdings, Inc.Email: info1@petvivo.com(952)
405-6216
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Mar 2024 to Apr 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Apr 2023 to Apr 2024